Conference Day One

Hari Persidangan 1

科学议程第一天

8:00 am Registration & Morning Coffee

8:45 am Chair’s Opening Remarks

  • Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

9:00 am Industry Leader’s Briefing: Reviewing the Current Cell Therapy Landscape Across Asia

  • James Li Co Founder & Chief Executive Officer, JW Therapeutics
  • Cecilia Zhang Chief Scientific Officer, Biosyngen
  • Christy Ma Chief Executive Officer, SCG Cell Therapy

Synopsis

To view full session details, download the agenda here

9:30 am Commercial Case Study: Immunotherapy for Cancer Cure & Beyond – A Historical Mission

  • Hao Shen Chief Scientific Officer, Fosun Kite Biotech

Synopsis

To view full session details, download the agenda here

Advancing Next Generation Cell Therapies for Autoimmune Disorders

10:00 am Clinical Case Study: JW Therapeutics, Phase 1 Autoimmune Clinical Trial Data – Using CD19 CAR-T Therapy to Treat SLE Patients in China

  • James Li Co Founder & Chief Executive Officer, JW Therapeutics

Synopsis

To view full session details, download the agenda here

10:30 am Morning Refreshments & Speed Networking

Synopsis

Take advantage of this dedicated networking session which will enable you to meet the key stakeholders in the room, allowing you to make introductions and identify who you would like to connect with across the meeting

11:30 am Advances and Clinical Applications of LNP Technologies in CAR-T Therapy

  • Sawyer Xie Chief Executive Officer, DaRen Biotech

Synopsis

To view full session details, download the agenda here

12:00 pm Preclinical Case Study: GF-CART01: Armoured CD19/CD20 Dual Targeting Non-Viral CAR T Therapy for B Cell Malignancy

Synopsis

To view full session details, download the agenda here

12:30 pm Lunch & Networking

Evaluating & Improving CAR Design to Increase Anti-Tumor Efficacy for Improved Toxicity Profiles

1:30 pm Pre-Clinical Case Study: Strategy for Designing and Developing Dual- Targeting CAR-T Cell Therapies to Improve Safety for Enhanced Clinical Outcomes

Synopsis

To view full session details, download the agenda here

2:00 pm Preclinical Case Study: Advancements in Vd2 Gamma Delta T Cell Therapy for In Vivo Activation and Allogeneic Treatments

  • Kok Fei Chan Research Fellow, Olivia Newton-John Cancer Research Institute

Synopsis

To view full session details, download the agenda here

2:30 pm Afternoon Refreshments & Poster Session

3:30 pm Roundtable Discussion: Matching the Optimum Indication for the Modality for Better Patient Response: T Cells vs NK Cells vs Gamma Delta Cells

Synopsis

To view full session details, download the agenda here

4:15 pm Enhancing Therapeutic Impact: Integrating Co-stimulatory Signalling in TCR-T Therapies

  • Wendell Yang President & Chief Executive Officer, Imgen BioSciences

Synopsis

To view full session details, download the agenda here

4:45 pm Chair’s Closing Remarks

  • Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research
DAY TWO